Table 2.
ETS and DoR distribution according to treatment.
| ETS and DoR Cut-Offs | All Patients n (%) | FOLFOXIRI n (%) | GemNab n (%) | p-Value |
|---|---|---|---|---|
| ETS | ||||
| ≥20% | 49 (35.5) | 32 (39.5) | 17 (29.8) | 0.28 |
| <20% | 89 (64.5) | 49 (60.5) | 40 (70.2) | |
| DoR | ||||
| I quartile (−81.81%–−44.87%) | 25 | 20 (34.5) | 5 (11.3) | 0.039 |
| II quartile (−44.87%–−27.52%) | 26 | 12 (20.7) | 14 (31.8) | |
| III quartile (−27.52%–−7.34%) | 26 | 15 (25.8) | 11 (25) | |
| IV quartile (−7.33%–+48%) | 25 | 11 (18.9) | 14 (31.8) | |
| ≥median | 51 | 32 (55.2) | 19 (43.2) | 0.23 |
| <median | 51 | 26 (44.8) | 25 (56.8) |
Abbreviations: GemNab, Gemcitabine Nab-Paclitaxel; ETS, early tumour shrinkage; DoR, depth of response.